ProCE Banner Activity

EASL 2021: Rapid Recap by Dr. Tarik Asselah

Multimedia
Hear a rapid update of the top HBV, HCV, and HDV studies from the Virtual 2021 International Liver Congress, 2021.

Released: July 20, 2021

Expiration: July 19, 2022

Share

Faculty

Tarik Asselah

Tarik Asselah, MD, PhD

Professor of Medicine
Department of Hepatology
Hôpital Beaujon
Université de Paris-Cité & INSERM 
Clichy, France

Supporters

AbbVie

Antios Therapeutics

Gilead Sciences, Inc.

Learning Objectives

Faculty Disclosure

Primary Author

Tarik Asselah, MD, PhD

Professor of Medicine
Department of Hepatology
Hôpital Beaujon
Université de Paris-Cité & INSERM 
Clichy, France

Tarik Asselah, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Eiger, Gilead Sciences, Janssen, MYR Pharmaceuticals, and Roche.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Elaine P. Seeskin,

Managing Editor, HIV
Clinical Care Options, LLC

Elaine P. Seeskin has no relevant conflicts of interest to report.

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B Stacy, PharmD, has no relevant conflicts of interest to report.